| Title |
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by MacrophagesVimseltinib is a Selective CSF1R Inhibitor for TGCT
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, August 2021
|
| DOI | 10.1158/1535-7163.mct-21-0361 |
| Pubmed ID | |
| Authors |
Bryan D. Smith, Michael D. Kaufman, Scott C. Wise, Yu Mi Ahn, Timothy M. Caldwell, Cynthia B. Leary, Wei-Ping Lu, Gege Tan, Lakshminarayana Vogeti, Subha Vogeti, Breelyn A. Wilky, Lara E. Davis, Maitreyi Sharma, Rodrigo Ruiz-Soto, Daniel L. Flynn |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 57% |
| Unknown | 3 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 57% |
| Scientists | 2 | 29% |
| Science communicators (journalists, bloggers, editors) | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 12% |
| Researcher | 2 | 12% |
| Student > Ph. D. Student | 1 | 6% |
| Student > Bachelor | 1 | 6% |
| Unknown | 11 | 65% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 2 | 12% |
| Agricultural and Biological Sciences | 2 | 12% |
| Medicine and Dentistry | 1 | 6% |
| Neuroscience | 1 | 6% |
| Chemistry | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 10 | 59% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2023.
All research outputs
#6,837,008
of 24,066,486 outputs
Outputs from Molecular Cancer Therapeutics
#1,483
of 3,943 outputs
Outputs of similar age
#134,002
of 419,132 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#19
of 55 outputs
Altmetric has tracked 24,066,486 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 3,943 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 419,132 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.